| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mental Disorders | 44 | 2023 | 6879 | 2.670 |
Why?
|
| Neurosciences | 14 | 2019 | 385 | 2.390 |
Why?
|
| Corpus Striatum | 22 | 2021 | 1238 | 1.650 |
Why?
|
| Enkephalins | 19 | 1999 | 139 | 1.630 |
Why?
|
| National Institute of Mental Health (U.S.) | 14 | 2018 | 108 | 1.460 |
Why?
|
| Brain Diseases | 5 | 2021 | 1553 | 1.340 |
Why?
|
| Schizophrenia | 19 | 2023 | 6986 | 1.260 |
Why?
|
| Cocaine | 17 | 2008 | 960 | 1.220 |
Why?
|
| Protein Precursors | 19 | 1999 | 1133 | 1.220 |
Why?
|
| Dopamine | 16 | 2007 | 1616 | 1.120 |
Why?
|
| Drug Discovery | 4 | 2014 | 1062 | 1.020 |
Why?
|
| Multifactorial Inheritance | 5 | 2021 | 1421 | 0.990 |
Why?
|
| Morals | 2 | 2021 | 289 | 0.940 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 13 | 1999 | 501 | 0.870 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 2 | 2015 | 264 | 0.860 |
Why?
|
| Brain | 46 | 2021 | 27438 | 0.800 |
Why?
|
| Autistic Disorder | 4 | 2021 | 1240 | 0.800 |
Why?
|
| Psychiatry | 10 | 2022 | 1714 | 0.780 |
Why?
|
| Anger | 2 | 2021 | 405 | 0.670 |
Why?
|
| Gene Expression Regulation | 29 | 2008 | 11930 | 0.660 |
Why?
|
| Nervous System Diseases | 4 | 2014 | 1668 | 0.650 |
Why?
|
| Substance-Related Disorders | 18 | 2011 | 4453 | 0.650 |
Why?
|
| Biology | 2 | 2021 | 291 | 0.640 |
Why?
|
| Nerve Tissue Proteins | 11 | 2015 | 4417 | 0.640 |
Why?
|
| Neurons | 23 | 2022 | 9504 | 0.640 |
Why?
|
| Genes, fos | 11 | 1998 | 176 | 0.590 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 5 | 2013 | 1994 | 0.580 |
Why?
|
| Receptors, Metabotropic Glutamate | 2 | 2012 | 195 | 0.580 |
Why?
|
| Human Genome Project | 3 | 2011 | 202 | 0.580 |
Why?
|
| Ethical Analysis | 1 | 2017 | 41 | 0.560 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 2046 | 0.560 |
Why?
|
| Synaptic Transmission | 6 | 2015 | 1173 | 0.540 |
Why?
|
| Obsessive-Compulsive Disorder | 3 | 2021 | 1509 | 0.540 |
Why?
|
| Neurobiology | 3 | 2013 | 138 | 0.520 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2016 | 123 | 0.510 |
Why?
|
| Research Support as Topic | 2 | 2016 | 699 | 0.510 |
Why?
|
| Animal Experimentation | 1 | 2015 | 46 | 0.490 |
Why?
|
| Research Personnel | 3 | 2015 | 591 | 0.490 |
Why?
|
| Psychotropic Drugs | 7 | 2003 | 888 | 0.480 |
Why?
|
| Neurotransmitter Agents | 7 | 2010 | 666 | 0.480 |
Why?
|
| Genetic Research | 1 | 2015 | 173 | 0.470 |
Why?
|
| Cocaine-Related Disorders | 5 | 2008 | 461 | 0.460 |
Why?
|
| Receptors, Neurotransmitter | 6 | 2005 | 174 | 0.460 |
Why?
|
| Neuronal Plasticity | 10 | 2022 | 1448 | 0.460 |
Why?
|
| Human Experimentation | 3 | 2018 | 124 | 0.450 |
Why?
|
| Reward | 5 | 2007 | 987 | 0.440 |
Why?
|
| Drug Industry | 3 | 2016 | 793 | 0.440 |
Why?
|
| Narcotics | 4 | 1997 | 337 | 0.440 |
Why?
|
| Biomedical Research | 4 | 2020 | 3463 | 0.440 |
Why?
|
| Animals | 95 | 2021 | 169418 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-fos | 7 | 1999 | 583 | 0.430 |
Why?
|
| Behavior | 4 | 2005 | 545 | 0.420 |
Why?
|
| Histone Deacetylase 2 | 1 | 2012 | 72 | 0.410 |
Why?
|
| Cyclic AMP | 10 | 1999 | 1468 | 0.400 |
Why?
|
| Glutamic Acid | 6 | 2003 | 1192 | 0.400 |
Why?
|
| Personal Autonomy | 2 | 2012 | 315 | 0.400 |
Why?
|
| Research | 7 | 2002 | 1984 | 0.390 |
Why?
|
| Genetics, Medical | 1 | 2014 | 334 | 0.390 |
Why?
|
| Gene Expression | 16 | 2002 | 7605 | 0.390 |
Why?
|
| Synapses | 7 | 2022 | 1766 | 0.380 |
Why?
|
| Memory | 5 | 2006 | 2210 | 0.380 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 3 | 1999 | 492 | 0.380 |
Why?
|
| Antipsychotic Agents | 3 | 2014 | 3077 | 0.380 |
Why?
|
| Humans | 144 | 2023 | 768451 | 0.370 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2019 | 794 | 0.370 |
Why?
|
| Terrorism | 2 | 2005 | 211 | 0.370 |
Why?
|
| Lie Detection | 1 | 2010 | 9 | 0.370 |
Why?
|
| Phenotype | 9 | 2022 | 16712 | 0.350 |
Why?
|
| Choice Behavior | 3 | 2012 | 846 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2022 | 18048 | 0.350 |
Why?
|
| Guilt | 1 | 2010 | 95 | 0.350 |
Why?
|
| Cyclins | 2 | 2003 | 606 | 0.340 |
Why?
|
| Central Nervous System Stimulants | 2 | 2012 | 1180 | 0.340 |
Why?
|
| Nootropic Agents | 1 | 2011 | 159 | 0.340 |
Why?
|
| Rats | 32 | 2018 | 23839 | 0.330 |
Why?
|
| Alternative Splicing | 3 | 2006 | 1094 | 0.330 |
Why?
|
| Hypothalamus | 4 | 1995 | 1004 | 0.320 |
Why?
|
| Violence | 1 | 2015 | 937 | 0.320 |
Why?
|
| Biotechnology | 1 | 2010 | 282 | 0.310 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 18388 | 0.310 |
Why?
|
| Enhancer Elements, Genetic | 8 | 1999 | 1368 | 0.310 |
Why?
|
| Depression | 5 | 2017 | 8235 | 0.300 |
Why?
|
| Models, Neurological | 6 | 2014 | 1784 | 0.300 |
Why?
|
| International Classification of Diseases | 2 | 2011 | 925 | 0.300 |
Why?
|
| Genes, Immediate-Early | 3 | 2001 | 102 | 0.290 |
Why?
|
| Grooming | 1 | 2007 | 38 | 0.290 |
Why?
|
| Stress, Physiological | 3 | 2006 | 1409 | 0.290 |
Why?
|
| Receptors, Dopamine D1 | 4 | 2005 | 292 | 0.280 |
Why?
|
| Volition | 1 | 2007 | 61 | 0.280 |
Why?
|
| Behavior, Addictive | 3 | 2007 | 467 | 0.270 |
Why?
|
| Child Behavior | 1 | 2012 | 862 | 0.270 |
Why?
|
| Receptors, Dopamine | 4 | 1996 | 296 | 0.270 |
Why?
|
| Depressive Disorder | 3 | 2017 | 3738 | 0.270 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2007 | 607 | 0.270 |
Why?
|
| Imipramine | 1 | 2006 | 98 | 0.260 |
Why?
|
| Adaptation, Physiological | 2 | 2007 | 1315 | 0.260 |
Why?
|
| Second Messenger Systems | 3 | 1995 | 204 | 0.260 |
Why?
|
| Association Learning | 2 | 2006 | 223 | 0.260 |
Why?
|
| Social Behavior | 2 | 2015 | 1144 | 0.260 |
Why?
|
| Schizophrenic Psychology | 3 | 2008 | 1652 | 0.250 |
Why?
|
| Models, Biological | 5 | 2018 | 9505 | 0.250 |
Why?
|
| Psychology, Clinical | 2 | 2019 | 43 | 0.250 |
Why?
|
| Serotonin | 4 | 2007 | 1047 | 0.250 |
Why?
|
| Compulsive Behavior | 2 | 2007 | 117 | 0.250 |
Why?
|
| Amphetamines | 3 | 1998 | 144 | 0.250 |
Why?
|
| Superior Cervical Ganglion | 2 | 1994 | 33 | 0.240 |
Why?
|
| Embryo, Mammalian | 5 | 2021 | 1674 | 0.230 |
Why?
|
| Amphetamine | 2 | 1996 | 224 | 0.230 |
Why?
|
| Neostriatum | 4 | 2007 | 247 | 0.230 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2008 | 298 | 0.230 |
Why?
|
| Transcription Factor AP-1 | 4 | 2003 | 321 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2005 | 8201 | 0.230 |
Why?
|
| Cognition | 5 | 2011 | 7066 | 0.230 |
Why?
|
| Phosphorylation | 16 | 2005 | 8332 | 0.230 |
Why?
|
| Social Responsibility | 1 | 2007 | 385 | 0.220 |
Why?
|
| Biological Psychiatry | 3 | 2017 | 27 | 0.220 |
Why?
|
| Adolescent Behavior | 1 | 2012 | 1192 | 0.220 |
Why?
|
| Social Environment | 1 | 2009 | 1026 | 0.220 |
Why?
|
| Growth Inhibitors | 3 | 1994 | 375 | 0.220 |
Why?
|
| Life Change Events | 1 | 2009 | 964 | 0.220 |
Why?
|
| Goals | 2 | 2007 | 715 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 478 | 0.220 |
Why?
|
| Genomics | 3 | 2022 | 5909 | 0.210 |
Why?
|
| Ethics Committees | 2 | 2000 | 51 | 0.210 |
Why?
|
| Brain Chemistry | 3 | 2000 | 962 | 0.210 |
Why?
|
| Health Services Needs and Demand | 2 | 2014 | 1408 | 0.210 |
Why?
|
| beta-Galactosidase | 5 | 1996 | 575 | 0.210 |
Why?
|
| Data Collection | 2 | 2023 | 3329 | 0.210 |
Why?
|
| Genes | 3 | 2000 | 1824 | 0.200 |
Why?
|
| Crack Cocaine | 1 | 2001 | 33 | 0.200 |
Why?
|
| Lymphokines | 3 | 1994 | 927 | 0.190 |
Why?
|
| Bipolar Disorder | 4 | 2023 | 5124 | 0.190 |
Why?
|
| Cognition Disorders | 4 | 2011 | 3985 | 0.190 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 1996 | 628 | 0.190 |
Why?
|
| Genetics | 1 | 2002 | 114 | 0.190 |
Why?
|
| Mental Health Services | 4 | 2002 | 1732 | 0.190 |
Why?
|
| Psychopharmacology | 1 | 2003 | 146 | 0.190 |
Why?
|
| DNA-Binding Proteins | 10 | 2002 | 9623 | 0.180 |
Why?
|
| Emotions | 5 | 2007 | 2773 | 0.180 |
Why?
|
| Transcription Factors | 10 | 2002 | 12174 | 0.180 |
Why?
|
| Maternal Exposure | 1 | 2008 | 1078 | 0.180 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2001 | 140 | 0.180 |
Why?
|
| Occupational Health Services | 1 | 2002 | 150 | 0.180 |
Why?
|
| Behavioral Sciences | 1 | 2000 | 29 | 0.180 |
Why?
|
| Mice, Transgenic | 10 | 2021 | 9558 | 0.180 |
Why?
|
| DiGeorge Syndrome | 1 | 2022 | 187 | 0.180 |
Why?
|
| Cholinergic Agents | 1 | 2021 | 97 | 0.180 |
Why?
|
| Cooperative Behavior | 2 | 2020 | 1514 | 0.180 |
Why?
|
| Calcium | 6 | 2005 | 5793 | 0.180 |
Why?
|
| Antidepressive Agents | 3 | 2014 | 2913 | 0.180 |
Why?
|
| Amines | 1 | 2001 | 280 | 0.170 |
Why?
|
| Receptors, Serotonin | 2 | 1998 | 209 | 0.170 |
Why?
|
| United States | 25 | 2019 | 73121 | 0.170 |
Why?
|
| Serotonin Antagonists | 2 | 1998 | 144 | 0.170 |
Why?
|
| Signal Transduction | 12 | 2007 | 23638 | 0.170 |
Why?
|
| Fear | 2 | 1998 | 1494 | 0.160 |
Why?
|
| Methylphenidate | 1 | 2003 | 491 | 0.160 |
Why?
|
| Penetrance | 1 | 2021 | 384 | 0.160 |
Why?
|
| Preimplantation Diagnosis | 1 | 2021 | 143 | 0.160 |
Why?
|
| Nervous System Malformations | 1 | 2001 | 244 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 7 | 2006 | 5803 | 0.160 |
Why?
|
| Phosphoserine | 1 | 1999 | 204 | 0.160 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2012 | 3742 | 0.160 |
Why?
|
| RNA, Messenger | 16 | 2008 | 12813 | 0.160 |
Why?
|
| Base Sequence | 15 | 1996 | 12428 | 0.160 |
Why?
|
| Databases as Topic | 1 | 2000 | 475 | 0.160 |
Why?
|
| Membrane Proteins | 2 | 2014 | 7895 | 0.150 |
Why?
|
| Cost of Illness | 4 | 2001 | 1960 | 0.150 |
Why?
|
| Molecular Sequence Data | 15 | 2001 | 17647 | 0.150 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 4 | 2007 | 905 | 0.150 |
Why?
|
| Immediate-Early Proteins | 2 | 1992 | 444 | 0.150 |
Why?
|
| Cells, Cultured | 14 | 2006 | 19041 | 0.150 |
Why?
|
| Ethics, Research | 1 | 1999 | 177 | 0.150 |
Why?
|
| Genetics, Behavioral | 3 | 2004 | 53 | 0.140 |
Why?
|
| Genome-Wide Association Study | 6 | 2022 | 12774 | 0.140 |
Why?
|
| Monosaccharide Transport Proteins | 5 | 1998 | 437 | 0.140 |
Why?
|
| RNA Polymerase II | 1 | 2001 | 547 | 0.140 |
Why?
|
| History, 21st Century | 2 | 2018 | 1575 | 0.140 |
Why?
|
| Peer Review, Research | 1 | 2020 | 342 | 0.140 |
Why?
|
| Genetic Testing | 3 | 2021 | 3586 | 0.140 |
Why?
|
| Nucleus Accumbens | 2 | 1997 | 372 | 0.140 |
Why?
|
| Amygdala | 3 | 2004 | 1382 | 0.140 |
Why?
|
| Mice | 19 | 2021 | 82045 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 1246 | 0.140 |
Why?
|
| History, 20th Century | 3 | 2018 | 2772 | 0.140 |
Why?
|
| Substance P | 2 | 1995 | 334 | 0.140 |
Why?
|
| Genetic Variation | 4 | 2021 | 6610 | 0.140 |
Why?
|
| Education | 1 | 1999 | 536 | 0.140 |
Why?
|
| src-Family Kinases | 1 | 1999 | 539 | 0.130 |
Why?
|
| Nervous System | 2 | 2006 | 547 | 0.130 |
Why?
|
| Learning | 2 | 2005 | 1762 | 0.130 |
Why?
|
| Denmark | 1 | 2019 | 778 | 0.130 |
Why?
|
| Models, Genetic | 3 | 2014 | 3442 | 0.130 |
Why?
|
| Confidentiality | 1 | 2000 | 606 | 0.130 |
Why?
|
| Public Health | 2 | 2007 | 2693 | 0.130 |
Why?
|
| Placebos | 2 | 2000 | 1668 | 0.130 |
Why?
|
| Interneurons | 1 | 2021 | 592 | 0.130 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2001 | 1140 | 0.130 |
Why?
|
| Health Priorities | 2 | 2014 | 379 | 0.130 |
Why?
|
| Animal Rights | 1 | 2015 | 10 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.130 |
Why?
|
| Mood Disorders | 2 | 2001 | 1128 | 0.130 |
Why?
|
| Twin Studies as Topic | 1 | 2015 | 103 | 0.130 |
Why?
|
| Blood-Brain Barrier | 6 | 1998 | 1034 | 0.130 |
Why?
|
| Genes, jun | 2 | 1992 | 69 | 0.130 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 1994 | 370 | 0.120 |
Why?
|
| Workplace | 1 | 2002 | 872 | 0.120 |
Why?
|
| Cues | 3 | 2007 | 884 | 0.120 |
Why?
|
| Privacy | 2 | 2010 | 233 | 0.120 |
Why?
|
| Liver Regeneration | 1 | 2016 | 214 | 0.120 |
Why?
|
| Choline O-Acetyltransferase | 2 | 1995 | 156 | 0.120 |
Why?
|
| Pan troglodytes | 1 | 2015 | 224 | 0.120 |
Why?
|
| Health Policy | 2 | 2014 | 2699 | 0.120 |
Why?
|
| Borderline Personality Disorder | 1 | 2002 | 775 | 0.120 |
Why?
|
| Alcoholism | 2 | 1995 | 1993 | 0.120 |
Why?
|
| Brassica | 1 | 1994 | 39 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1994 | 3735 | 0.120 |
Why?
|
| Aging | 5 | 2009 | 8761 | 0.120 |
Why?
|
| Biomedical Technology | 1 | 2016 | 210 | 0.110 |
Why?
|
| Central Nervous System Agents | 1 | 2014 | 74 | 0.110 |
Why?
|
| Genetic Linkage | 3 | 2002 | 2342 | 0.110 |
Why?
|
| Chromatin | 1 | 2006 | 2969 | 0.110 |
Why?
|
| Neural Pathways | 2 | 2006 | 3122 | 0.110 |
Why?
|
| Neurosecretory Systems | 1 | 1995 | 223 | 0.110 |
Why?
|
| Haloperidol | 2 | 1993 | 394 | 0.110 |
Why?
|
| Observer Variation | 2 | 2010 | 2622 | 0.110 |
Why?
|
| Software | 2 | 2019 | 4463 | 0.110 |
Why?
|
| Behavior, Animal | 3 | 2008 | 1882 | 0.110 |
Why?
|
| Genetic Engineering | 1 | 1999 | 936 | 0.110 |
Why?
|
| Ethics, Medical | 1 | 1999 | 785 | 0.110 |
Why?
|
| Vasoactive Intestinal Peptide | 5 | 1994 | 179 | 0.110 |
Why?
|
| Psychotic Disorders | 2 | 2023 | 3278 | 0.110 |
Why?
|
| Inheritance Patterns | 1 | 2015 | 341 | 0.110 |
Why?
|
| Clinical Trials as Topic | 5 | 2003 | 8051 | 0.110 |
Why?
|
| Dopamine Agonists | 3 | 2005 | 353 | 0.110 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 1998 | 484 | 0.110 |
Why?
|
| Alleles | 2 | 2022 | 6890 | 0.110 |
Why?
|
| Stress, Psychological | 2 | 2007 | 4538 | 0.110 |
Why?
|
| Fertilization in Vitro | 1 | 2021 | 1297 | 0.110 |
Why?
|
| Substantia Nigra | 1 | 1994 | 348 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 2834 | 0.100 |
Why?
|
| Diagnostic Imaging | 2 | 2004 | 3543 | 0.100 |
Why?
|
| Genitalia, Male | 1 | 1992 | 87 | 0.100 |
Why?
|
| Models, Psychological | 2 | 2008 | 835 | 0.100 |
Why?
|
| Drug Repositioning | 1 | 2014 | 244 | 0.100 |
Why?
|
| Consciousness | 1 | 2018 | 603 | 0.100 |
Why?
|
| Peptic Ulcer | 1 | 1994 | 222 | 0.100 |
Why?
|
| PC12 Cells | 2 | 2003 | 317 | 0.100 |
Why?
|
| Genes, Synthetic | 1 | 1992 | 88 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 1395 | 0.100 |
Why?
|
| Psychophysiologic Disorders | 1 | 1994 | 223 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 1993 | 323 | 0.100 |
Why?
|
| Clozapine | 2 | 1993 | 508 | 0.100 |
Why?
|
| Anxiety | 3 | 2007 | 4655 | 0.100 |
Why?
|
| Dextroamphetamine | 1 | 1992 | 134 | 0.100 |
Why?
|
| Forecasting | 5 | 2002 | 2950 | 0.100 |
Why?
|
| Transfection | 6 | 2005 | 5767 | 0.100 |
Why?
|
| Organoids | 1 | 2018 | 749 | 0.100 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 3 | 1999 | 121 | 0.100 |
Why?
|
| Neuropeptides | 2 | 1994 | 950 | 0.100 |
Why?
|
| Genitalia, Female | 1 | 1992 | 146 | 0.100 |
Why?
|
| Chromosome Mapping | 5 | 2008 | 4622 | 0.090 |
Why?
|
| Cognitive Science | 2 | 2002 | 15 | 0.090 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2001 | 2538 | 0.090 |
Why?
|
| Mutation | 2 | 2015 | 30243 | 0.090 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 2 | 2005 | 54 | 0.090 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 823 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2005 | 452 | 0.090 |
Why?
|
| Cerebrospinal Fluid | 3 | 1989 | 545 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 1995 | 947 | 0.090 |
Why?
|
| Activating Transcription Factor 1 | 2 | 2002 | 26 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-jun | 3 | 1999 | 287 | 0.090 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 1890 | 0.090 |
Why?
|
| Helicobacter pylori | 1 | 1994 | 382 | 0.090 |
Why?
|
| Interleukin-6 | 3 | 1994 | 3234 | 0.090 |
Why?
|
| Helicobacter Infections | 1 | 1994 | 392 | 0.090 |
Why?
|
| Rett Syndrome | 2 | 2006 | 164 | 0.090 |
Why?
|
| Dopamine Antagonists | 2 | 2005 | 289 | 0.090 |
Why?
|
| In Situ Hybridization | 4 | 1995 | 1906 | 0.090 |
Why?
|
| Drug Interactions | 3 | 2005 | 1421 | 0.080 |
Why?
|
| Animals, Newborn | 5 | 2008 | 2696 | 0.080 |
Why?
|
| Genome, Human | 3 | 2017 | 4453 | 0.080 |
Why?
|
| Informed Consent | 4 | 2018 | 1012 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2010 | 36840 | 0.080 |
Why?
|
| Psychotherapy | 3 | 2007 | 1656 | 0.080 |
Why?
|
| Ciliary Neurotrophic Factor | 5 | 1996 | 77 | 0.080 |
Why?
|
| ras Proteins | 1 | 1994 | 1058 | 0.080 |
Why?
|
| Phorbol Esters | 1 | 1989 | 109 | 0.080 |
Why?
|
| DNA | 6 | 2003 | 7213 | 0.080 |
Why?
|
| Benzazepines | 2 | 2005 | 311 | 0.080 |
Why?
|
| Environmental Exposure | 1 | 2023 | 4533 | 0.080 |
Why?
|
| Binding Sites | 5 | 2006 | 6030 | 0.080 |
Why?
|
| Replication Protein C | 1 | 2008 | 26 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2014 | 2656 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2016 | 1138 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2010 | 962 | 0.070 |
Why?
|
| Central Nervous System | 1 | 1995 | 1348 | 0.070 |
Why?
|
| World Health Organization | 2 | 2011 | 1328 | 0.070 |
Why?
|
| Enzyme Inhibitors | 3 | 2005 | 3734 | 0.070 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2005 | 4636 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2039 | 0.070 |
Why?
|
| Cross-Cultural Comparison | 1 | 2011 | 639 | 0.070 |
Why?
|
| Motivation | 2 | 2014 | 2034 | 0.070 |
Why?
|
| International Cooperation | 1 | 2014 | 1439 | 0.070 |
Why?
|
| Brain Mapping | 3 | 2004 | 6740 | 0.070 |
Why?
|
| Drive | 1 | 2007 | 34 | 0.070 |
Why?
|
| Supraoptic Nucleus | 3 | 1999 | 28 | 0.070 |
Why?
|
| Maryland | 1 | 2007 | 277 | 0.070 |
Why?
|
| Nerve Growth Factors | 3 | 1994 | 566 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2022 | 16029 | 0.070 |
Why?
|
| Stochastic Processes | 1 | 2008 | 359 | 0.070 |
Why?
|
| Maternal Behavior | 1 | 2009 | 309 | 0.070 |
Why?
|
| Risk Factors | 7 | 2015 | 74915 | 0.070 |
Why?
|
| Environment | 2 | 2003 | 1126 | 0.070 |
Why?
|
| Disease Progression | 1 | 2023 | 13655 | 0.070 |
Why?
|
| Activating Transcription Factor 2 | 2 | 1997 | 44 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2010 | 20231 | 0.070 |
Why?
|
| Awareness | 1 | 2010 | 654 | 0.070 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2006 | 122 | 0.070 |
Why?
|
| Transcription, Genetic | 7 | 1997 | 7599 | 0.070 |
Why?
|
| Leukemia Inhibitory Factor | 3 | 1994 | 81 | 0.070 |
Why?
|
| Protein Kinase C | 2 | 2005 | 1207 | 0.060 |
Why?
|
| Neuropsychology | 1 | 2007 | 110 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2016 | 2589 | 0.060 |
Why?
|
| Receptors, Dopamine D2 | 3 | 1994 | 486 | 0.060 |
Why?
|
| Hospitals, Psychiatric | 1 | 2007 | 318 | 0.060 |
Why?
|
| Ventral Tegmental Area | 1 | 2007 | 136 | 0.060 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 2005 | 93 | 0.060 |
Why?
|
| Prefrontal Cortex | 2 | 2007 | 2251 | 0.060 |
Why?
|
| Proteomics | 1 | 2019 | 3901 | 0.060 |
Why?
|
| Phenylacetates | 1 | 2005 | 112 | 0.060 |
Why?
|
| Dynorphins | 1 | 2005 | 82 | 0.060 |
Why?
|
| Internal-External Control | 1 | 2007 | 359 | 0.060 |
Why?
|
| Oligonucleotide Probes | 2 | 1996 | 417 | 0.060 |
Why?
|
| Cholera Toxin | 1 | 1987 | 562 | 0.060 |
Why?
|
| Fragile X Syndrome | 1 | 2006 | 116 | 0.060 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2005 | 142 | 0.060 |
Why?
|
| Dicarboxylic Acids | 1 | 2005 | 75 | 0.060 |
Why?
|
| Massachusetts | 1 | 2018 | 8908 | 0.060 |
Why?
|
| Disabled Persons | 1 | 2014 | 1218 | 0.060 |
Why?
|
| Judgment | 1 | 2007 | 273 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 4780 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 1677 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 1089 | 0.060 |
Why?
|
| Comorbidity | 1 | 2019 | 10601 | 0.060 |
Why?
|
| Glutamates | 1 | 2005 | 385 | 0.060 |
Why?
|
| Drug Tolerance | 2 | 1996 | 367 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 1670 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 1987 | 692 | 0.060 |
Why?
|
| DNA Mutational Analysis | 4 | 2002 | 4120 | 0.060 |
Why?
|
| Benzoates | 1 | 2005 | 213 | 0.050 |
Why?
|
| Cloning, Molecular | 3 | 1996 | 4175 | 0.050 |
Why?
|
| Facial Expression | 2 | 1998 | 515 | 0.050 |
Why?
|
| Recurrence | 2 | 2007 | 8510 | 0.050 |
Why?
|
| Saline Solution, Hypertonic | 2 | 1994 | 114 | 0.050 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2003 | 29 | 0.050 |
Why?
|
| Kinetics | 6 | 1999 | 6348 | 0.050 |
Why?
|
| Carrier Proteins | 3 | 2006 | 4948 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2005 | 5042 | 0.050 |
Why?
|
| Potassium Chloride | 1 | 2003 | 229 | 0.050 |
Why?
|
| Limbic System | 2 | 1996 | 423 | 0.050 |
Why?
|
| RNA | 3 | 2022 | 2727 | 0.050 |
Why?
|
| Rats, Inbred Strains | 4 | 1992 | 2087 | 0.050 |
Why?
|
| Child | 5 | 2021 | 80863 | 0.050 |
Why?
|
| Lithium | 2 | 1996 | 600 | 0.050 |
Why?
|
| Biomedical Enhancement | 1 | 2002 | 8 | 0.050 |
Why?
|
| Pregnancy | 6 | 2005 | 30179 | 0.050 |
Why?
|
| Neuropharmacology | 1 | 2002 | 20 | 0.050 |
Why?
|
| Choroid Plexus | 2 | 1998 | 248 | 0.050 |
Why?
|
| Time | 1 | 2003 | 546 | 0.050 |
Why?
|
| Response Elements | 1 | 2003 | 308 | 0.050 |
Why?
|
| Finland | 1 | 2023 | 609 | 0.050 |
Why?
|
| Career Mobility | 2 | 2020 | 262 | 0.050 |
Why?
|
| Adoption | 1 | 2002 | 97 | 0.050 |
Why?
|
| Male | 29 | 2012 | 364781 | 0.050 |
Why?
|
| Glycine | 1 | 2005 | 672 | 0.050 |
Why?
|
| Somatostatin | 3 | 1994 | 448 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 5532 | 0.050 |
Why?
|
| Opioid-Related Disorders | 1 | 1996 | 2188 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 706 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 2173 | 0.050 |
Why?
|
| Early Growth Response Protein 1 | 2 | 1992 | 133 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2003 | 716 | 0.050 |
Why?
|
| Arginine Vasopressin | 2 | 1991 | 126 | 0.050 |
Why?
|
| Macromolecular Substances | 1 | 2003 | 1435 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 2477 | 0.040 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2000 | 88 | 0.040 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2001 | 167 | 0.040 |
Why?
|
| Patient Advocacy | 2 | 1999 | 362 | 0.040 |
Why?
|
| Research Design | 3 | 2022 | 6217 | 0.040 |
Why?
|
| Twins | 1 | 2002 | 340 | 0.040 |
Why?
|
| Acetates | 1 | 2001 | 318 | 0.040 |
Why?
|
| Personnel Selection | 1 | 2002 | 201 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2000 | 4249 | 0.040 |
Why?
|
| Cerebral Cortex | 3 | 2003 | 5827 | 0.040 |
Why?
|
| Mind-Body Relations, Metaphysical | 1 | 2000 | 36 | 0.040 |
Why?
|
| Purines | 1 | 2003 | 614 | 0.040 |
Why?
|
| COS Cells | 1 | 2001 | 1136 | 0.040 |
Why?
|
| Psychophysiology | 1 | 2000 | 137 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 1994 | 792 | 0.040 |
Why?
|
| Fetus | 2 | 1998 | 1883 | 0.040 |
Why?
|
| Immunohistochemistry | 8 | 1998 | 11138 | 0.040 |
Why?
|
| Quinones | 1 | 1999 | 78 | 0.040 |
Why?
|
| Disaster Planning | 1 | 2005 | 560 | 0.040 |
Why?
|
| Phenylethanolamine N-Methyltransferase | 2 | 1990 | 18 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 1999 | 166 | 0.040 |
Why?
|
| Rifabutin | 1 | 1999 | 59 | 0.040 |
Why?
|
| Synaptic Potentials | 1 | 2019 | 44 | 0.040 |
Why?
|
| Rabbits | 8 | 1999 | 4786 | 0.040 |
Why?
|
| Synaptosomes | 1 | 2019 | 116 | 0.040 |
Why?
|
| Salicylamides | 2 | 1998 | 33 | 0.040 |
Why?
|
| Psychopathology | 1 | 2022 | 435 | 0.040 |
Why?
|
| Tissue Distribution | 5 | 1996 | 2298 | 0.040 |
Why?
|
| Nomifensine | 1 | 1998 | 14 | 0.040 |
Why?
|
| Ethics, Clinical | 1 | 1999 | 101 | 0.040 |
Why?
|
| Ritanserin | 1 | 1998 | 10 | 0.040 |
Why?
|
| Financing, Organized | 1 | 2020 | 206 | 0.040 |
Why?
|
| Tropanes | 1 | 1998 | 48 | 0.040 |
Why?
|
| Mentally Ill Persons | 1 | 1999 | 126 | 0.040 |
Why?
|
| Knowledge Bases | 1 | 2019 | 97 | 0.040 |
Why?
|
| Benzoquinones | 1 | 1999 | 198 | 0.040 |
Why?
|
| N-Methylaspartate | 1 | 1999 | 231 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 5 | 1998 | 186 | 0.040 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 1 | 1998 | 45 | 0.040 |
Why?
|
| Oxidopamine | 2 | 1998 | 173 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 3763 | 0.040 |
Why?
|
| Receptors, Glutamate | 2 | 1996 | 228 | 0.040 |
Why?
|
| Phosphoproteins | 2 | 1998 | 2450 | 0.040 |
Why?
|
| Iodine | 1 | 2000 | 287 | 0.040 |
Why?
|
| Omentum | 1 | 1999 | 168 | 0.040 |
Why?
|
| Endothelium, Vascular | 5 | 1998 | 4425 | 0.040 |
Why?
|
| Alzheimer Disease | 2 | 2014 | 8721 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2001 | 664 | 0.040 |
Why?
|
| Oncostatin M | 2 | 1994 | 42 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2016 | 10494 | 0.040 |
Why?
|
| Symporters | 1 | 2000 | 363 | 0.040 |
Why?
|
| Capillaries | 3 | 1998 | 756 | 0.040 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 1999 | 197 | 0.040 |
Why?
|
| Mental Competency | 1 | 1999 | 179 | 0.040 |
Why?
|
| Lactams, Macrocyclic | 1 | 1999 | 318 | 0.040 |
Why?
|
| Bioethics | 1 | 2019 | 118 | 0.040 |
Why?
|
| Female | 21 | 2012 | 396943 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2000 | 504 | 0.040 |
Why?
|
| Chromosome Aberrations | 2 | 2002 | 1781 | 0.040 |
Why?
|
| Leucine Zippers | 1 | 1997 | 116 | 0.040 |
Why?
|
| Administrative Personnel | 1 | 1998 | 185 | 0.040 |
Why?
|
| Organizational Policy | 1 | 1999 | 434 | 0.030 |
Why?
|
| Hematoporphyrins | 2 | 1988 | 23 | 0.030 |
Why?
|
| Chimera | 1 | 2018 | 454 | 0.030 |
Why?
|
| Tegmentum Mesencephali | 1 | 1996 | 59 | 0.030 |
Why?
|
| Mental Health | 1 | 2011 | 3271 | 0.030 |
Why?
|
| Social Support | 1 | 2007 | 2195 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2006 | 3664 | 0.030 |
Why?
|
| Arteriosclerosis | 2 | 1993 | 1056 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6242 | 0.030 |
Why?
|
| National Health Programs | 1 | 2000 | 442 | 0.030 |
Why?
|
| Hippocampus | 2 | 2006 | 3783 | 0.030 |
Why?
|
| Dizocilpine Maleate | 1 | 1996 | 173 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 1999 | 436 | 0.030 |
Why?
|
| Budgets | 1 | 1998 | 232 | 0.030 |
Why?
|
| 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 1 | 1995 | 7 | 0.030 |
Why?
|
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 1995 | 16 | 0.030 |
Why?
|
| Autoradiography | 2 | 1995 | 732 | 0.030 |
Why?
|
| Habituation, Psychophysiologic | 1 | 1996 | 148 | 0.030 |
Why?
|
| Chlordiazepoxide | 1 | 1995 | 42 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 13452 | 0.030 |
Why?
|
| Career Choice | 1 | 2002 | 769 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 3 | 1996 | 4534 | 0.030 |
Why?
|
| Conditioning, Classical | 1 | 1998 | 370 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1997 | 440 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 3826 | 0.030 |
Why?
|
| Ownership | 1 | 2018 | 343 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 1997 | 585 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 14728 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1999 | 1251 | 0.030 |
Why?
|
| Receptors, Opioid, mu | 1 | 1996 | 171 | 0.030 |
Why?
|
| RNA Probes | 1 | 1995 | 111 | 0.030 |
Why?
|
| Indole Alkaloids | 1 | 1994 | 23 | 0.030 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1994 | 56 | 0.030 |
Why?
|
| Quinpirole | 1 | 1994 | 32 | 0.030 |
Why?
|
| Ergolines | 1 | 1994 | 57 | 0.030 |
Why?
|
| Cell Line | 2 | 2022 | 15609 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2019 | 946 | 0.030 |
Why?
|
| Diazepam | 1 | 1995 | 215 | 0.030 |
Why?
|
| Basal Ganglia | 1 | 1997 | 555 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 13026 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2016 | 441 | 0.030 |
Why?
|
| Locus Coeruleus | 1 | 1996 | 234 | 0.030 |
Why?
|
| Morphine | 2 | 1996 | 658 | 0.030 |
Why?
|
| Adolescent | 5 | 2011 | 89168 | 0.030 |
Why?
|
| Ondansetron | 1 | 1994 | 95 | 0.030 |
Why?
|
| Narcotic Antagonists | 2 | 1999 | 590 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2006 | 3697 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2000 | 1172 | 0.030 |
Why?
|
| Injections, Intraventricular | 2 | 1999 | 227 | 0.030 |
Why?
|
| Levodopa | 1 | 1994 | 223 | 0.030 |
Why?
|
| Patient Care | 1 | 1999 | 629 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1995 | 699 | 0.030 |
Why?
|
| Staurosporine | 1 | 1994 | 241 | 0.030 |
Why?
|
| Educational Status | 1 | 2021 | 2519 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1998 | 530 | 0.030 |
Why?
|
| Osmotic Pressure | 1 | 1994 | 137 | 0.030 |
Why?
|
| Hematoporphyrin Photoradiation | 1 | 1993 | 17 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 15460 | 0.030 |
Why?
|
| Alkaloids | 1 | 1994 | 192 | 0.030 |
Why?
|
| Death | 1 | 2018 | 683 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 3922 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 1999 | 3594 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2002 | 6035 | 0.030 |
Why?
|
| Peptides | 3 | 1994 | 4368 | 0.030 |
Why?
|
| Carbazoles | 1 | 1994 | 221 | 0.030 |
Why?
|
| Isoquinolines | 1 | 1994 | 354 | 0.030 |
Why?
|
| Amino Acid Isomerases | 1 | 1992 | 31 | 0.030 |
Why?
|
| Receptors, Dopamine D4 | 1 | 1993 | 169 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 1999 | 14480 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1997 | 1170 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 1994 | 6135 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1998 | 1444 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2008 | 10784 | 0.030 |
Why?
|
| Blood Volume | 1 | 1994 | 546 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2019 | 1750 | 0.020 |
Why?
|
| Psychometrics | 1 | 2002 | 3072 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 1999 | 770 | 0.020 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 1992 | 97 | 0.020 |
Why?
|
| Naloxone | 1 | 1994 | 371 | 0.020 |
Why?
|
| Suicide, Attempted | 1 | 2001 | 1409 | 0.020 |
Why?
|
| Neuroblastoma | 3 | 1994 | 1265 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1994 | 462 | 0.020 |
Why?
|
| Time Factors | 6 | 2008 | 40271 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 1999 | 4861 | 0.020 |
Why?
|
| Nuclear Proteins | 3 | 1993 | 5808 | 0.020 |
Why?
|
| Antimanic Agents | 1 | 1995 | 524 | 0.020 |
Why?
|
| Astrocytes | 1 | 1999 | 1354 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 1999 | 2216 | 0.020 |
Why?
|
| Up-Regulation | 2 | 1999 | 4138 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2002 | 2665 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 1994 | 564 | 0.020 |
Why?
|
| Family | 1 | 2002 | 3208 | 0.020 |
Why?
|
| Calcimycin | 1 | 1990 | 214 | 0.020 |
Why?
|
| Adenosine | 1 | 1995 | 816 | 0.020 |
Why?
|
| Chromaffin System | 1 | 1990 | 15 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1992 | 1553 | 0.020 |
Why?
|
| Protein Binding | 2 | 2006 | 9376 | 0.020 |
Why?
|
| Indoles | 1 | 1998 | 1834 | 0.020 |
Why?
|
| Pineal Gland | 1 | 1991 | 158 | 0.020 |
Why?
|
| Cold Temperature | 1 | 1994 | 786 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 1993 | 1992 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 1992 | 577 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 12242 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 2203 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 1997 | 1728 | 0.020 |
Why?
|
| Plasmids | 1 | 1995 | 2269 | 0.020 |
Why?
|
| Calmodulin | 1 | 1990 | 241 | 0.020 |
Why?
|
| Catheterization, Peripheral | 1 | 1993 | 346 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 1995 | 1139 | 0.020 |
Why?
|
| Species Specificity | 2 | 1998 | 2422 | 0.020 |
Why?
|
| Drug Synergism | 2 | 1990 | 1765 | 0.020 |
Why?
|
| Oximes | 1 | 1990 | 304 | 0.020 |
Why?
|
| Adult | 11 | 2004 | 223542 | 0.020 |
Why?
|
| HIV Infections | 1 | 1995 | 17564 | 0.020 |
Why?
|
| Health Care Reform | 1 | 1998 | 1256 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2000 | 9687 | 0.020 |
Why?
|
| Deoxyribonuclease I | 1 | 1989 | 225 | 0.020 |
Why?
|
| Swine | 1 | 2018 | 5996 | 0.020 |
Why?
|
| Age Factors | 3 | 2008 | 18478 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2008 | 127 | 0.020 |
Why?
|
| Microscopy, Electron | 3 | 1998 | 2565 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1992 | 1972 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2016 | 2575 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1987 | 71 | 0.020 |
Why?
|
| Ferricyanides | 1 | 1987 | 31 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1996 | 2434 | 0.020 |
Why?
|
| Electrophysiology | 1 | 1990 | 1266 | 0.020 |
Why?
|
| Parkinson Disease | 1 | 2001 | 2891 | 0.020 |
Why?
|
| Hypotension, Controlled | 1 | 1987 | 16 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1988 | 1144 | 0.020 |
Why?
|
| Trans-Activators | 1 | 1996 | 2858 | 0.020 |
Why?
|
| Physicians | 2 | 2002 | 4615 | 0.020 |
Why?
|
| Nitroprusside | 1 | 1987 | 272 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1988 | 767 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1991 | 705 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2008 | 276 | 0.020 |
Why?
|
| Glucose | 2 | 1998 | 4355 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1995 | 2030 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 1989 | 551 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1987 | 1305 | 0.020 |
Why?
|
| Cats | 1 | 1987 | 978 | 0.020 |
Why?
|
| Orbit | 1 | 1989 | 459 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 4 | 1998 | 2737 | 0.020 |
Why?
|
| Genotype | 1 | 2000 | 13047 | 0.020 |
Why?
|
| Dextrans | 1 | 1987 | 574 | 0.020 |
Why?
|
| Phototherapy | 1 | 1988 | 369 | 0.020 |
Why?
|
| Locomotion | 1 | 2008 | 391 | 0.020 |
Why?
|
| Encephalitis | 1 | 1989 | 441 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2008 | 752 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2009 | 459 | 0.010 |
Why?
|
| Seizures | 1 | 1998 | 2996 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3590 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1993 | 2889 | 0.010 |
Why?
|
| Animals, Suckling | 2 | 1994 | 69 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1987 | 676 | 0.010 |
Why?
|
| Depressive Disorder, Major | 1 | 2002 | 4816 | 0.010 |
Why?
|
| Piperazines | 1 | 1994 | 2546 | 0.010 |
Why?
|
| Prevalence | 1 | 2000 | 15880 | 0.010 |
Why?
|
| Drainage | 1 | 1989 | 1179 | 0.010 |
Why?
|
| Ion Channels | 1 | 1988 | 1044 | 0.010 |
Why?
|
| Mannitol | 3 | 1991 | 177 | 0.010 |
Why?
|
| Publishing | 1 | 2009 | 836 | 0.010 |
Why?
|
| Gastric Stump | 1 | 1961 | 8 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 14766 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2019 | 22293 | 0.010 |
Why?
|
| Duodenal Ulcer | 1 | 1961 | 121 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 7451 | 0.010 |
Why?
|
| Dihematoporphyrin Ether | 2 | 1993 | 33 | 0.010 |
Why?
|
| Ascites | 1 | 1963 | 339 | 0.010 |
Why?
|
| Dogs | 1 | 2006 | 3847 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 7134 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1990 | 2170 | 0.010 |
Why?
|
| Biological Transport | 2 | 1998 | 2089 | 0.010 |
Why?
|
| Action Potentials | 1 | 1988 | 1837 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1992 | 4572 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 1999 | 65409 | 0.010 |
Why?
|
| Serum Albumin, Radio-Iodinated | 1 | 1999 | 37 | 0.010 |
Why?
|
| Chromium Radioisotopes | 1 | 1999 | 34 | 0.010 |
Why?
|
| Cytokines | 1 | 1994 | 7449 | 0.010 |
Why?
|
| Guinea Pigs | 2 | 1991 | 1310 | 0.010 |
Why?
|
| Sugar Acids | 1 | 1999 | 24 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 1999 | 151 | 0.010 |
Why?
|
| Societies | 1 | 1999 | 107 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 1999 | 133 | 0.010 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 1998 | 29 | 0.010 |
Why?
|
| Financial Support | 1 | 1999 | 116 | 0.010 |
Why?
|
| Financing, Government | 1 | 2002 | 473 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1998 | 306 | 0.010 |
Why?
|
| Raclopride | 1 | 1998 | 101 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1998 | 22365 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5308 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1999 | 278 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 1999 | 26351 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 1994 | 5709 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1998 | 42623 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 1998 | 190 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 6091 | 0.010 |
Why?
|
| Cell Polarity | 1 | 2000 | 639 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 24311 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 1998 | 245 | 0.010 |
Why?
|
| Thyrotropin | 1 | 2000 | 834 | 0.010 |
Why?
|
| Mentors | 1 | 2002 | 672 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1998 | 329 | 0.010 |
Why?
|
| Papio | 1 | 1998 | 671 | 0.010 |
Why?
|
| Gastrectomy | 1 | 1961 | 696 | 0.010 |
Why?
|
| Perfusion | 2 | 1991 | 1402 | 0.010 |
Why?
|
| Medical Records | 1 | 1961 | 1413 | 0.010 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1998 | 478 | 0.010 |
Why?
|
| Anesthesia | 1 | 1987 | 1596 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 1996 | 343 | 0.010 |
Why?
|
| Happiness | 1 | 1996 | 170 | 0.010 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1994 | 71 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1999 | 1035 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1998 | 842 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1998 | 1502 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1995 | 229 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 1998 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1994 | 317 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1995 | 348 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 6995 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 1996 | 561 | 0.010 |
Why?
|
| Weaning | 1 | 1993 | 103 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1994 | 565 | 0.010 |
Why?
|
| Diet, Atherogenic | 1 | 1993 | 92 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 1669 | 0.010 |
Why?
|
| Codeine | 1 | 1972 | 51 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1993 | 527 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 1996 | 873 | 0.010 |
Why?
|
| Erythrocyte Membrane | 1 | 1994 | 438 | 0.010 |
Why?
|
| Visual Pathways | 1 | 1996 | 559 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1995 | 499 | 0.010 |
Why?
|
| Heroin | 1 | 1972 | 120 | 0.010 |
Why?
|
| Heart Rate | 2 | 1998 | 4218 | 0.010 |
Why?
|
| X Chromosome | 1 | 1995 | 819 | 0.010 |
Why?
|
| Fiber Optic Technology | 1 | 1993 | 291 | 0.010 |
Why?
|
| Laparoscopy | 1 | 1963 | 2056 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1961 | 1484 | 0.010 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 1991 | 87 | 0.010 |
Why?
|
| Clomipramine | 1 | 1990 | 54 | 0.010 |
Why?
|
| 1-Naphthylamine | 1 | 1990 | 48 | 0.010 |
Why?
|
| Tunica Intima | 1 | 1993 | 459 | 0.010 |
Why?
|
| Fluvoxamine | 1 | 1990 | 78 | 0.010 |
Why?
|
| Education, Medical | 1 | 2002 | 1742 | 0.010 |
Why?
|
| Visual Cortex | 1 | 1998 | 1112 | 0.010 |
Why?
|
| Injections, Intravenous | 2 | 1988 | 1379 | 0.010 |
Why?
|
| Methadone | 1 | 1972 | 322 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1993 | 627 | 0.010 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 1993 | 329 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 1995 | 871 | 0.010 |
Why?
|
| Mathematics | 1 | 1991 | 704 | 0.010 |
Why?
|
| Subarachnoid Space | 1 | 1989 | 80 | 0.010 |
Why?
|
| Aged | 2 | 2001 | 171520 | 0.010 |
Why?
|
| Sertraline | 1 | 1990 | 209 | 0.010 |
Why?
|
| Tritium | 2 | 1984 | 707 | 0.000 |
Why?
|
| Radiopharmaceuticals | 1 | 1999 | 2731 | 0.000 |
Why?
|
| Glioma | 1 | 1984 | 3523 | 0.000 |
Why?
|
| Sheep | 1 | 1991 | 1451 | 0.000 |
Why?
|
| Blood Pressure | 2 | 1998 | 8538 | 0.000 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1988 | 826 | 0.000 |
Why?
|
| Gene Deletion | 1 | 1994 | 2674 | 0.000 |
Why?
|
| Fluoxetine | 1 | 1990 | 735 | 0.000 |
Why?
|
| Oxygen | 1 | 1998 | 4269 | 0.000 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1987 | 243 | 0.000 |
Why?
|
| Developmental Disabilities | 1 | 1995 | 1516 | 0.000 |
Why?
|
| Cell Differentiation | 2 | 1994 | 11674 | 0.000 |
Why?
|
| Catecholamines | 1 | 1987 | 390 | 0.000 |
Why?
|
| Optic Nerve | 1 | 1989 | 572 | 0.000 |
Why?
|
| Meta-Analysis as Topic | 1 | 1990 | 1364 | 0.000 |
Why?
|
| Adrenal Glands | 1 | 1987 | 557 | 0.000 |
Why?
|
| Escherichia coli Infections | 1 | 1989 | 524 | 0.000 |
Why?
|
| Hematoporphyrin Derivative | 1 | 1984 | 10 | 0.000 |
Why?
|
| Muscles | 1 | 1988 | 1582 | 0.000 |
Why?
|
| Drug Stability | 1 | 1984 | 291 | 0.000 |
Why?
|
| Rats, Inbred F344 | 1 | 1984 | 826 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1984 | 9182 | 0.000 |
Why?
|
| Cattle | 1 | 1987 | 3830 | 0.000 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1984 | 350 | 0.000 |
Why?
|
| Lipids | 1 | 1993 | 3346 | 0.000 |
Why?
|
| Aorta | 1 | 1988 | 2046 | 0.000 |
Why?
|
| Middle Aged | 3 | 2004 | 223418 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1990 | 2780 | 0.000 |
Why?
|
| Acute Disease | 1 | 1989 | 7246 | 0.000 |
Why?
|
| Epilepsy | 1 | 1994 | 3324 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1991 | 5152 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1990 | 12450 | 0.000 |
Why?
|
| Cohort Studies | 1 | 1996 | 41797 | 0.000 |
Why?
|
| Neoplasms | 1 | 1961 | 22386 | 0.000 |
Why?
|
| Carbon Isotopes | 1 | 1972 | 459 | 0.000 |
Why?
|
| Carotid Arteries | 1 | 1972 | 943 | 0.000 |
Why?
|